Treatment-resistant depression: therapeutic trends, challenges, and future directions
- PMID: 22654508
- PMCID: PMC3363299
- DOI: 10.2147/PPA.S29716
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Abstract
Background: Patients with major depression respond to antidepressant treatment, but 10%-30% of them do not improve or show a partial response coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. The aim of this paper is to review the therapeutic options for treating resistant major depressive disorder, as well as evaluating further therapeutic options.
Methods: In addition to Google Scholar and Quertle searches, a PubMed search using key words was conducted, and relevant articles published in English peer-reviewed journals (1990-2011) were retrieved. Only those papers that directly addressed treatment options for treatment-resistant depression were retained for extensive review.
Results: Treatment-resistant depression, a complex clinical problem caused by multiple risk factors, is targeted by integrated therapeutic strategies, which include optimization of medications, a combination of antidepressants, switching of antidepressants, and augmentation with non-antidepressants, psychosocial and cultural therapies, and somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, and vagus nerve stimulation. As a corollary, more than a third of patients with treatment-resistant depression tend to achieve remission and the rest continue to suffer from residual symptoms. The latter group of patients needs further study to identify the most effective therapeutic modalities. Newer biomarker-based antidepressants and other drugs, together with non-drug strategies, are on the horizon to address further the multiple complex issues of treatment-resistant depression.
Conclusion: Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.
Keywords: antidepressants; biomarkers; somatic therapies; therapeutic options; treatment-resistant depression.
Similar articles
-
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.World J Psychiatry. 2015 Sep 22;5(3):330-41. doi: 10.5498/wjp.v5.i3.330. World J Psychiatry. 2015. PMID: 26425446 Free PMC article.
-
Therapeutic options for treatment-resistant depression.CNS Drugs. 2010 Feb;24(2):131-61. doi: 10.2165/11530280-000000000-00000. CNS Drugs. 2010. PMID: 20088620 Review.
-
Neuromodulation therapies and treatment-resistant depression.Med Devices (Auckl). 2012;5:53-65. doi: 10.2147/MDER.S33198. Epub 2012 Jul 13. Med Devices (Auckl). 2012. PMID: 23152710 Free PMC article.
-
Management of Treatment-Resistant Depression: Challenges and Strategies.Neuropsychiatr Dis Treat. 2020 Jan 21;16:221-234. doi: 10.2147/NDT.S198774. eCollection 2020. Neuropsychiatr Dis Treat. 2020. PMID: 32021216 Free PMC article. Review.
-
Therapeutic Efficacy of Neurostimulation for Depression: Techniques, Current Modalities, and Future Challenges.Neurosci Bull. 2016 Feb;32(1):115-26. doi: 10.1007/s12264-015-0009-2. Epub 2016 Jan 19. Neurosci Bull. 2016. PMID: 26781880 Free PMC article. Review.
Cited by
-
Investigation of Herb-Drug Interactions between Xylopia aethiopica, Its Principal Constituent Xylopic Acid, and Antidepressants.Adv Pharmacol Pharm Sci. 2024 May 25;2024:9923801. doi: 10.1155/2024/9923801. eCollection 2024. Adv Pharmacol Pharm Sci. 2024. PMID: 38826835 Free PMC article.
-
Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets.Psychopharmacology (Berl). 2024 May 27. doi: 10.1007/s00213-024-06617-6. Online ahead of print. Psychopharmacology (Berl). 2024. PMID: 38801530 Review.
-
Neuroactive Steroids, Toll-like Receptors, and Neuroimmune Regulation: Insights into Their Impact on Neuropsychiatric Disorders.Life (Basel). 2024 Apr 30;14(5):582. doi: 10.3390/life14050582. Life (Basel). 2024. PMID: 38792602 Free PMC article. Review.
-
Evaluation of New Approaches to Depression Treatment Using an Animal Model of Pharmacoresistant Depression.Int J Mol Sci. 2024 May 12;25(10):5265. doi: 10.3390/ijms25105265. Int J Mol Sci. 2024. PMID: 38791304 Free PMC article.
-
Rationale and design of a double-blinded, randomized placebo-controlled trial of 40 Hz light neurostimulation therapy for depression (FELIX).Ann Med. 2024 May 11;56(1):2354852. doi: 10.1080/07853890.2024.2354852. Epub 2024 May 20. Ann Med. 2024. PMID: 38767238 Free PMC article.
References
-
- Souery D, Amsterdam J, deMontigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83–91. - PubMed
-
- O’Reardon JP, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatr Ann. 1998;28:633–640.
-
- Nelson JC. Combined drug treatment strategies for major depression. Psych Ann. 1998;28:197–202.
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association; 2000. Practice Guideline for the Treatment of Patients with Major Depression; p. 2000. Text Revision.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials